Xavier RCMI Center for Cancer Research

泽维尔 RCMI 癌症研究中心

• 批准号: 8843952
• 负责人: Gene D'Amour
• 金额: $ 219.77万
• 依托单位: XAVIER UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-24 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8843952
• 关键词: African American; Area; Binding; Bioinformatics; Biological Sciences; Biomedical Research; Caucasians; Cellular biology; Center for Translational Science Activities; Cessation of life; Clinical Sciences; Collaborations; Communities; Core Facility; Data Collection; Development; Disease; Drug Delivery Systems; Drug Design; Faculty; Funding; Goals; Grant; Growth; Health; Health Sciences; Individual; Institution; Investments; Knowledge; Laboratories; Lead; Louisiana; Malignant Neoplasms; Measurable; Medical; Mentors; Minority; Molecular Biology; NCI Center for Cancer Research; Outcome; Peer Review; Pharmacists; Pilot Projects; Population; Process; Productivity; Program Development; Public Health; Recording of previous events; Research; Research Personnel; Research Project Grants; Research Support; Resources; Science, Technology, Engineering and Mathematics; Scientist; Series; Services; Source; Strategic Planning; Structure; Support System; Technology Transfer; Time; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Vision; Work; anticancer research; cancer health disparity; driving force; drug discovery; health disparity; improved; innovation; meetings; minority health; programs; public health relevance; tool

DESCRIPTION (provided by applicant): Since its inception in 2009, Xavier University's RCIVII Center for Cancer Research has been a driving force toward achieving the University's goal of becoming a national leader in cancer and health disparities research. We propose five alms in order to move closer to attaining this goal. (1) Strengthen internal and external collaborations and partnerships, particularly those that promote health disparities and translational research: building on existing collaborations with LSU, LSU Health Sciences Center, Tulane University and the Pennington Biomedical Research Center through active partnerships in the Louisiana Cancer Research Consortium and the Louisiana Biomedical Research Network, we will leverage research and mentoring resources in place and establish new ones via partnerships formed within Xavier and between Xavier and RTRN institutions. (2) Reorganize and enhance critical core facilities: we will down size one existing core, create a new core in drug discovery and delivery and add -a bioinformatics facility to our existing Cell and Molecular Biology Core. (3) Increase Xavier's pool of competitive and productive cancer and health disparities researchers who participate in the translational research "pipeline:" we will retain previously hired, now competitive, RCMI faculty, hire additional promising junior faculty in critical "gap" areas that will improve our capabilities in health disparities and translational research, and provide these faculty with the resources necessary to become/remain competitive. (4)Establish a new pilot project program for cancer/health disparities research: we will use a peer-reviewed mechanism to select projects that will increase Xavier NIH R01 and other R-series grants and support pilot translational research projects for preliminary data collection. (5) Provide targeted administrative services in support of RCMI investigators: we will assure that faculty needs are met with minimal burden, research programs and core services are integrated and encourage teamwork, and that faculty development programs promote professional growth and engagement in health disparities and translational research. Successfully completing these aims will be significant because it will increase the pool of researchers who can more quickly translate bench discoveries into public benefit, particularly in minority communities. The research projects supported by the present RCMI proposal will be innovative as we propose to utilize a programmatic structure involving partnerships with major research universities, an NIH-supported Center for Minority Health and Health Disparities and an NIH-funded center for translational sciences.

简介（由申请人提供）：自2009年成立以来，泽维尔大学的RCIVII癌症研究中心一直致力于实现大学成为癌症和健康差异研究的全国领导者的目标。为了更接近实现这一目标，我们提出了五项布施。(1)加强内部和外部合作与伙伴关系，特别是那些促进保健差距和转化研究的合作与伙伴关系；在与路易斯安那州立大学、路易斯安那州立大学健康科学中心、杜兰大学和彭宁顿生物医学研究中心现有合作的基础上，通过与路易斯安那州癌症研究联盟和路易斯安那州生物医学研究网络的积极合作，我们将利用现有的研究和指导资源，并通过在泽维尔大学内部以及泽维尔大学和RTRN机构之间建立新的合作伙伴关系。(2)重组和加强关键核心设施：我们将缩小现有核心设施的规模，在药物发现和递送方面创建一个新的核心设施，并在现有的细胞和分子生物学核心设施上增加一个生物信息学设施。(3)增加泽维尔大学参与转化研究“管道”的具有竞争力和生产力的癌症和健康差异研究人员的数量：我们将保留以前雇用的、现在具有竞争力的RCMI教师，在关键的“差距”领域雇用更多有前途的年轻教师，以提高我们在健康差异和转化研究方面的能力，并为这些教师提供必要的资源，以保持竞争力。(4)建立新的癌症/健康差异研究试点项目：我们将采用同行评议机制来选择项目，这些项目将增加Xavier NIH R01和其他r系列资助，并支持初步数据收集的试点转化研究项目。(5)提供针对性